<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medications associated with dyspareunia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medications associated with dyspareunia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Medications associated with dyspareunia</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1">Category or mechanism</td> <td class="subtitle1">Specific medications or classes of medications</td> <td class="subtitle1">Comment</td> </tr> <tr> <td>Medications that may induce vulvovaginal atrophy</td> <td> <ul> <li>Aromatase inhibitors </li> <li>Gonadotropin-releasing hormone agonists or antagonists </li> <li>Some chemotherapeutic agents </li> <li>Tamoxifen </li> <li>Depot medroxyprogesterone acetate </li> </ul> </td> <td> <p>If menopause is induced, vaginal atrophy will result. If the effect is temporary, these changes will reverse when the medication is discontinued.</p> <p>Some chemotherapeutic agents result in premature ovarian failure.</p> <p>In premenopausal women, tamoxifen has an anti-estrogenic effect on the vaginal epithelium, resulting in atrophy<sup>[1]</sup>. In contrast, in postmenopausal women, tamoxifen has an estrogenic effect on the vaginal epithelium. This results in increased vaginal discharge. Some postmenopausal women who are taking tamoxifen develop recurrent candidal vulvovaginitis, with resultant dyspareunia.</p> <p>Depot medroxyprogesterone acetate suppresses the hypothalamic-pituitary axis, which induces hypoestrogenism and vaginal atrophy.</p> </td> </tr> <tr> <td>Oral contraceptives</td> <td> </td> <td>Some data suggest that oral contraceptives are associated with vestibulodynia. The mechanism of this is unclear<sup>[2]</sup>. These findings have not been investigated for other formulations of estrogen-progestin contraceptives (patch, vaginal ring).</td> </tr> <tr> <td>Anticholinergics</td> <td> <ul> <li>Anti-histamines (eg, diphenhydramine, chlorpheniramine) </li> <li>Amitriptyline </li> </ul> </td> <td>May result in vaginal dryness and dyspareunia.</td> </tr> <tr> <td>Medications that increase the risk of recurrent candidal vulvovaginitis</td> <td> <ul> <li>Immunosuppressants (eg, glucocorticoids, TNF-alpha inhibitors) </li> <li>Antibiotics </li> </ul> </td> <td>Candidal vulvovaginitis is associated with the development of vulvodynia.</td> </tr> <tr> <td>Topical agents that cause irritant or allergic reactions</td> <td> <ul> <li>Spermicides </li> </ul> </td> <td> </td> </tr> <tr> <td>Medications that may result in painful clitoral tumescence<sup>[3-9]</sup></td> <td> <ul> <li>Serotonergic agents (Citalopram, Nefazodone, Trazodone) </li> <li>Dopaminergic agents (Bupropion, Bromocriptine, Olanzapine) </li> </ul> </td> <td> </td> </tr> <tr> <td>Antihypertensives</td> <td> </td> <td>Sexual dysfunction appears to occur more frequently in hypertensive women. It is unclear whether this is associated with the hypertension itself or with antihypertensive medications.</td> </tr> </tbody></table></div><div class="graphic_reference">References:<br/><ol>
<li>Mourits MJ, De Vries EG, Willemse PH, et al. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001; 97:855. </li>
<li>Goldstein A, Burrows L, Goldstein I. Can oral contraceptives cause vestibulodynia? J Sex Med 2010; 7:1585. </li>
<li>Berk M, Acton M. Citalopram-associated clitoral priapism: a case series. Int Clin Psychopharmacol 1997; 12:121. </li>
<li>Brodie-Meijer CC, Diemont WL, Buijs PJ. Nefazodone-induced clitoral priapism. Int Clin Psychopharmacol 1999; 14:257. </li>
<li>Battaglia C, Venturoli S. Persistent genital arousal disorder and trazodone. Morphometric and vascular modifications of the clitoris. A case report. J Sex Med 2009; 6:2896. </li>
<li>Pescatori ES, Engelman JC, Davis G, Goldstein I. Priapism of the clitoris: a case report following trazodone use. J Urol 1993; 149:1557. </li>
<li>Levenson JL. Priapism associated with bupropion treatment. Am J Psychiatry 1995; 152:813. </li>
<li>Blin O, Schwertschlag US, Serratrice G. Painful clitoral tumescence during bromocriptine therapy. Lancet 1991; 18:1231. </li>
<li>Bucur M, Mahmood T. Olanzapine-induced clitoral priapism. J Clin Psychopharmacol 2004; 24:572. </li></ol></div><div id="graphicVersion">Graphic 62991 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
